AC
XERS icon

Aristides Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Aristides Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,080
Closed -$293K – 300
2021
Q4 		$293K Buy
+100,080
New +$216K 0.13% 146

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristides Capital's XERS Position: Q1 2022 in Review

Aristides Capital sold out of Xeris Biopharma Holdings (XERS) in Q1 2022, closing a stake of 100,080 shares — an estimated $293K sold.

Aristides Capital first reported a position in XERS in Q4 2021 and held it in 1 quarter. The position peaked at $293K in Q4 2021. 103 funds tracked by Wall St. Rank hold XERS as of Q1 2022.

  • Aristides Capital reported no remaining Xeris Biopharma Holdings position as of Q1 2022 after selling out during the quarter.
  • Aristides Capital sold 100,080 Xeris Biopharma Holdings shares in Q1 2022, an estimated $293K.
  • Aristides Capital first reported a position in Xeris Biopharma Holdings in Q4 2021 and held it in 1 quarter.
  • Aristides Capital's Xeris Biopharma Holdings position peaked at $293K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.